522 related articles for article (PubMed ID: 35012356)
1. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
2. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
[TBL] [Abstract][Full Text] [Related]
3. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands.
Queirós-Reis L; Mesquita JR; Brancale A; Bassetto M
J Chem Inf Model; 2023 Dec; 63(23):7282-7298. PubMed ID: 37991468
[TBL] [Abstract][Full Text] [Related]
5. Calpain-2 mediates SARS-CoV-2 entry via regulating ACE2 levels.
Zeng Q; Antia A; Casorla-Perez LA; Puray-Chavez M; Kutluay SB; Ciorba MA; Ding S
mBio; 2024 Mar; 15(3):e0228723. PubMed ID: 38349185
[TBL] [Abstract][Full Text] [Related]
6. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
7. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.
Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH
Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550
[TBL] [Abstract][Full Text] [Related]
8. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
[TBL] [Abstract][Full Text] [Related]
10. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
11. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
12. Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry.
Ratnapriya S; Braun AR; Cervera Benet H; Carlson D; Ding S; Paulson CN; Mishra N; Sachs JN; Aldrich CC; Finzi A; Herschhorn A
ACS Infect Dis; 2022 Oct; 8(10):2045-2058. PubMed ID: 36153947
[TBL] [Abstract][Full Text] [Related]
13. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
[TBL] [Abstract][Full Text] [Related]
15. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
[TBL] [Abstract][Full Text] [Related]
16. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
[TBL] [Abstract][Full Text] [Related]
17. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
Freidel MR; Armen RS
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
[TBL] [Abstract][Full Text] [Related]
18. Spike protein mediated membrane fusion during SARS-CoV-2 infection.
Li X; Yuan H; Li X; Wang H
J Med Virol; 2023 Jan; 95(1):e28212. PubMed ID: 36224449
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
20. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
Bi W; Chen G; Dang B
J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
